openPR Logo
Press release

Spasticity Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

12-20-2022 11:49 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Spasticity Pipeline Drugs and Companies Insight Report (2022):

Spasticity pipeline constitutes 20+ key companies continuously working towards developing 20+ Spasticity treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Spasticity Overview
Spasticity is a condition in which there is an abnormal increase in muscle tone or stiffness of muscle, which might interfere with movement, speech, or be associated with discomfort or pain. Spasticity is usually caused by damage to nerve pathways within the brain or spinal cord that control muscle movement. Spasticity can present variably in a clinical setting, sometimes with a subtle neurological manifestation and, other times, with severely increased muscle tone leading to immobility of joints

"Spasticity Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spasticity Market.

The Spasticity Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Spasticity Pipeline Report: https://www.delveinsight.com/report-store/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Spasticity treatment therapies with a considerable amount of success over the years. Spasticity Key players such as - Lundbeck, Revance Therapeutics, Ipsen, Saol Therapeutics, Huons, and others, are developing therapies for the Spasticity treatment
• Spasticity Emerging therapies such as - Lu AG06466, DAXXIFY, IPN10200, SIL 1002, HU-014, and others are expected to have a significant impact on the Spasticity market in the coming years.
• In July 2021, Huons initiated a multi-center, Phase III clinical trial to evaluate the safety and efficacy ofHU-014 Inj in the Treatment of Post Stroke Upper Limb Spasticity. HU-014 Inj was given an injection to 5 Upper limbmuscle (Total 360U/, IM)
• In April 2021, Aquavit Holdings LLC announced that it acquired an exclusive license to register, market and commercializea botulinum toxin in the United States and Canada. Aquavit has been investing in its proprietary delivery technologies and related intellectual property for botulinum toxin and recently proved its efficacy and safety through a clinical study

Spasticity Pipeline Therapeutics Assessment
• Spasticity Assessment by Product Type
• Spasticity By Stage and Product Type
• Spasticity Assessment by Route of Administration
• Spasticity By Stage and Route of Administration
• Spasticity Assessment by Molecule Type
• Spasticity by Stage and Molecule Type

DelveInsight's Spasticity Report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Emerging Spasticity Drugs Under Different Phases of Clinical Development Include:
• Lu AG06466: Lundbeck
• DAXXIFY: Revance Therapeutics
• IPN10200: Ipsen
• SIL 1002: Saol Therapeutics
• HU-014: Huons

Get a Free Sample PDF Report to know more about Spasticity Pipeline Assessment- https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Spasticity Pipeline Analysis:
The Spasticity pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Spasticity treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spasticity Treatment.
• Spasticity key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Spasticity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spasticity market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Spasticity product details are provided in the report. Download the Spasticity pipeline report to learn more about the emerging Spasticity therapies at:
https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Spasticity Pipeline Market Drivers
• Increasing prevalence of stroke, multiple sclerosis, and brain injury drive the market
• Increasing R&D for developing effective therapies

Spasticity Pipeline Market Barriers
• High cost of the treatment
• Lack of disease awareness in emerging economies

Scope of Spasticity Pipeline Drug Insight
• Coverage: Global
• Key Spasticity Companies: Lundbeck, Revance Therapeutics, Ipsen, Saol Therapeutics, Huons, and others
• Key Spasticity Therapies: Lu AG06466, DAXXIFY, IPN10200, SIL 1002, HU-014, and others
• Spasticity Therapeutic Assessment: Spasticity current marketed and Spasticity emerging therapies
• Spasticity Market Dynamics: Spasticity market drivers and Spasticity market barriers

Request for Sample PDF Report for Spasticity Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Spasticity Report Introduction
2 Spasticity Executive Summary
3 Spasticity Overview
4 Spasticity- Analytical Perspective In-depth Commercial Assessment
5 Spasticity Pipeline Therapeutics
6 Spasticity Late Stage Products (Phase II/III)
7 Spasticity Mid Stage Products (Phase II)
8 Spasticity Early Stage Products (Phase I)
9 Spasticity Preclinical Stage Products
10 Spasticity Therapeutics Assessment
11 Spasticity Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Spasticity Key Companies
14 Spasticity Key Products
15 Spasticity Unmet Needs
16 Spasticity Market Drivers and Barriers
17 Spasticity Future Perspectives and Conclusion
18 Spasticity Analyst Views
19 Appendix
20 About DelveInsight

Download Sample PDF Report to know more about Spasticity drugs and therapies- https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Related Reports:

Spasticity Market https://www.delveinsight.com/report-store/spasticity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Spasticity-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Spasticity Epidemiology https://www.delveinsight.com/report-store/spasticity-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Spasticity Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"DelveInsight's 'Ventricular Assist Devices (VAD) Market Insight, Competitive Landscape and Market Forecast - 2027' report delivers an in-depth understanding of Ventricular Assist Devices and the historical and forecasted Ventricular Assist Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Vein Illumination Devices - Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Basal Cell Carcinoma (Basal Cell Epithelioma) Market
https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Basal Cell Carcinoma (Basal Cell Epithelioma) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Basal Cell Carcinoma (Basal Cell Epithelioma), historical and forecasted epidemiology as well as the Basal Cell Carcinoma (Basal Cell Epithelioma) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Contact Us:

Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Spasticity Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments here

News-ID: 2856737 • Views:

More Releases from DelveInsight Business Research

Global Advanced Melanoma Pipeline Accelerates With 60+ Emerging Therapies, Reveals DelveInsight's 2025 Analysis
Global Advanced Melanoma Pipeline Accelerates With 60+ Emerging Therapies, Revea …
DelveInsight's "Advanced Melanoma Pipeline Insight 2025" report delivers an in-depth analysis of more than 55 companies and over 60 investigational therapies currently advancing through the Advanced Melanoma research landscape. It offers detailed profiles of both clinical- and preclinical-stage candidates and provides a thorough evaluation of therapies based on product type, development stage, route of administration, and molecule class. The report also outlines inactive or discontinued programs within this domain. Explore the
Global Spasticity Treatment Landscape Set for Transformation: DelveInsight Unveils Insights into 12+ Pipeline Therapies
Global Spasticity Treatment Landscape Set for Transformation: DelveInsight Unvei …
DelveInsight's "Spasticity Pipeline Insight, 2025" report offers an in-depth evaluation of 10+ companies and more than 12 investigational therapies currently advancing through the Spasticity treatment pipeline. The report includes detailed profiles of clinical- and preclinical-stage candidates, along with a thorough assessment of therapies by product type, development phase, route of administration, and molecular class. It also highlights discontinued and inactive programs in the field. Stay informed with the latest developments! Access
Lewy Body Dementia Treatment Market 2034 - Market Size, Competitive Landscape, Clinical Trials, Market Dynamics, Epidemiology, Companies | DelveInsight
Lewy Body Dementia Treatment Market 2034 - Market Size, Competitive Landscape, C …
The Lewy Body Dementia (LBD) market across the seven major markets (7MM) was valued at approximately USD 670 million in 2022, with strong growth anticipated through 2034. In 2022, an estimated 11 million dementia cases were recorded across the 7MM, of which ~0.6 million were attributed to Lewy Body Dementia. Rising disease prevalence-driven by aging demographics, enhanced diagnostic capabilities, and increasing awareness-is expected to stimulate market expansion. Companies including EIP
Bronchitis Treatment Market 2034: Market Size, Competitive Landscape, Companies, Clinical Trials, FDA Aprrovasls and Future Outlook by DelveInsight
Bronchitis Treatment Market 2034: Market Size, Competitive Landscape, Companies, …
The bronchitis therapeutics market is projected to grow steadily from 2025-2034, driven by rising disease prevalence, technological progress, and the emergence of new treatment options. Current management focuses on symptom relief through bronchodilators, corticosteroids, and antibiotics for acute cases, while chronic bronchitis requires long-term inhaled therapies, pulmonary rehabilitation, and lifestyle changes. A key advancement is the FDA-approved OHTUVAYRE (ensifentrine), which offers dual bronchodilator and anti-inflammatory benefits. Despite progress, there is

All 5 Releases


More Releases for Spasticity

Spasticity Market 2025-2034 Business Outlook, Critical Insight and Growth
Introduction Spasticity is a motor disorder characterized by involuntary muscle stiffness, spasms, and exaggerated reflexes caused by damage to the central nervous system (CNS). It frequently occurs as a complication of stroke, multiple sclerosis (MS), cerebral palsy, traumatic brain or spinal cord injury, and other neurological conditions. Spasticity can severely impact mobility, daily functioning, and quality of life, making it a significant healthcare burden worldwide. Treatment approaches combine pharmacological agents, intrathecal therapies,
Muscle Spasticity Market Emerging Trends and Growth Prospects 2034
Introduction Muscle spasticity is a condition characterized by involuntary muscle stiffness, spasms, and increased tone, often resulting from neurological disorders such as multiple sclerosis, cerebral palsy, stroke, or traumatic brain and spinal cord injuries. It significantly impacts mobility and quality of life, making effective management essential. With the rising incidence of neurological diseases and advancements in physiotherapy, drug therapies, and medical devices, the global muscle spasticity market is witnessing steady expansion. According
Spasticity Drugs Market Segments, Growth and Trends by Forecast by 2031
The report is segmented By Drug Type (Baclofen, Botulinum Toxin, Diazepam, Tizanidine, Dantrolene Sodium, and Others), Route of Administration (Oral, Intramuscular, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments. Get Sample Copy -https://www.theinsightpartners.com/sample/TIPRE00040811/?utm_source=OpenPR&utm_medium=10831 Major Companies operating in the Spasticity Drugs Market are: Ipsen Pharma Allergan Acorda Therapeutics,
Spasticity Drugs Top Companies Regional and Data Analysis to 2031
The Spasticity Drugs Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. Download PDF Brochure at: https://www.theinsightpartners.com/sample/TIPRE00040811/?utm_source=OpenPR&utm_medium=10129 Major Companies operating in the Spasticity Drugs Market are: • Ipsen Pharma • Allergan • Acorda Therapeutics, Inc. • Merz Pharma • Teva Pharmaceutical Industries Ltd. • Novartis AG • Sun Pharmaceutical Industries Ltd. • Beximco Pharmaceuticals Ltd. • Johnson & Johnson Private Limited • Zydus Cadila Contact Us: If you have any queries about this report or if
Spasticity Treatment Market Expecting Huge Demand in Upcoming Years
The Global Spasticity Treatment Market size is estimated at $5.7 Billion in 2025 and is forecast to register an annual growth rate (CAGR) of 4.9% to reach $8.8 Billion by 2034. Download now The latest study released on the Global Spasticity Treatment Market by USD Analytics Market evaluates market size, trend, and forecast to 2034. The Spasticity Treatment market study covers significant research data and proofs to be a handy resource
Muscle Spasticity Market Growth, Research Report, Analysis & Trends 2023-2033
Muscle Spasticity Market Report Overview:       Report Attribute Details Base Year 2022 Forecast Years